EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

How many people have a Huntington's Disease expansion: A population-based prevalence study in Northern Scotland

Heather Cruickshank, Zosia Miedzybrodzka

Neuroepidemiology · 2024

DOI: 10.1159/000542739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroepidemiology, 2024. Verfasst von Heather Cruickshank und 1 weiteren Autor:innen. Beteiligte Einrichtung: North of Scotland Regional Genetics Service, Clinical Genetics, Aberdeen, UK, heather.cruickshank@nhs.scot. Hauptthemen laut MEDLINE: Huntington Disease. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous work demonstrated a prevalence of 14.6 per 100,000 manifest Huntington’s disease (HD) patients and 8.3 per 100,000 identified pre-symptomatic gene expansion carriers (IPGEC) in Northern Scotland. Many of those at high risk of having a huntingtin (HTT) gene expansion remain untested with the exact number being unknown.

Objectives

To estimate how many people in Northern Scotland are at 50% risk of having a HTT gene expansion to help with HD clinic service planning and to calculate how many people could access an effective treatment if available.

Methods

Clinical and pedigree records from the North of Scotland Genetic Clinic were examined to estimate numbers of manifest HD patients, IPGEC, and individuals at 50% risk.

Results

The prevalence of those at 50% risk living in Northern Scotland was 45.2 per 100,000 people. Every manifest HD patient in Northern Scotland has 4.4 relatives at 50% risk and every patient with a HTT gene expansion has 2.9 relatives at 50% risk. There are up to 415 (46.2 per 100,000) adults who could access an effective treatment if available, but this number is likely to be an underestimate as not all manifesting individuals seek diagnosis.

Conclusions

Despite high predictive testing rates, at least 2.2 adults are living with the HTT gene expansion for every one of the 14.5 per 100,000 manifest HD patients in Northern Scotland. Regional variation in rates and ascertainment need to be factored into future service planning, including: genetic counselling and testing, management, and treatment delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseHumansScotlandPrevalenceMaleFemaleHuntingtin ProteinAdultMiddle AgedAged

Stichwörter der Autor:innen

GeneticsHuntington’s diseaseNorthern ScotlandPopulation-based studiesPrevalence

Substanzen

Huntingtin ProteinHTT protein, human

Autor:innen und Institutionen

  • North of Scotland Regional Genetics Service, Clinical Genetics, Aberdeen, UK, heather.cruickshank@nhs.scot.
  • North of Scotland Regional Genetics Service, Clinical Genetics, Aberdeen, UK, zosia@abdn.ac.uk.
  • Medical Genetics Group, School of Medicine, Medical Sciences, Nutrition and Dentistry, University of Aberdeen, Aberdeen, UK, zosia@abdn.ac.uk.

Zitieren

APA

Cruickshank, H., & Miedzybrodzka, Z. (2024). How many people have a Huntington's Disease expansion: A population-based prevalence study in Northern Scotland. Neuroepidemiology. https://doi.org/10.1159/000542739

Vancouver

Cruickshank H, Miedzybrodzka Z. How many people have a Huntington's Disease expansion: A population-based prevalence study in Northern Scotland. Neuroepidemiology. 2024. doi:10.1159/000542739

BibTeX
@article{Cruickshank2024,
  author = {Cruickshank, Heather and Miedzybrodzka, Zosia},
  title = {How many people have a Huntington's Disease expansion: A population-based prevalence study in Northern Scotland},
  journal = {Neuroepidemiology},
  year = {2024},
  doi = {10.1159/000542739}
}
Kostenlos starten →